PMID- 27539303
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 2193-8261 (Print)
IS  - 2193-6544 (Electronic)
IS  - 2193-6544 (Linking)
VI  - 5
IP  - 2
DP  - 2016 Dec
TI  - Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A 
      Systematic Review.
PG  - 161-168
AB  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that 
      have been extensively investigated for the treatment of hyperglycemia in type 2 
      diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal 
      glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond 
      glycemic control, these drugs have other beneficial effects on cardiovascular 
      (CV) risk factors. The present review discusses the potential role of SGLT2 
      inhibitors in treating CV complications (acute and chronic) associated with T2DM. 
      FUNDING: AstraZeneca Pharma India Ltd.
FAU - Kalra, Sanjay
AU  - Kalra S
AD  - Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India. 
      brideknl@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160818
PL  - England
TA  - Cardiol Ther
JT  - Cardiology and therapy
JID - 101634495
EIN - Cardiol Ther. 2016 Dec;5(2):169. PMID: 27620898
PMC - PMC5125111
OTO - NOTNLM
OT  - Blood pressure
OT  - Cardiovascular diseases
OT  - Sodium-glucose cotransporter 2 (SGLT2) inhibitors
OT  - Treatment
EDAT- 2016/08/20 06:00
MHDA- 2016/08/20 06:01
PMCR- 2016/08/18
CRDT- 2016/08/20 06:00
PHST- 2016/06/11 00:00 [received]
PHST- 2016/08/20 06:00 [pubmed]
PHST- 2016/08/20 06:01 [medline]
PHST- 2016/08/20 06:00 [entrez]
PHST- 2016/08/18 00:00 [pmc-release]
AID - 10.1007/s40119-016-0069-z [pii]
AID - 69 [pii]
AID - 10.1007/s40119-016-0069-z [doi]
PST - ppublish
SO  - Cardiol Ther. 2016 Dec;5(2):161-168. doi: 10.1007/s40119-016-0069-z. Epub 2016 
      Aug 18.